Hot Features
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-m... Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.5 | -10.6382978723 | 4.7 | 4.74 | 4.14 | 540767 | 4.43992981 | CS |
| 4 | -1.14 | -21.3483146067 | 5.34 | 5.52 | 4.14 | 782158 | 4.84757714 | CS |
| 12 | -1.15 | -21.4953271028 | 5.35 | 5.685 | 4.14 | 671368 | 5.07637244 | CS |
| 26 | -1.15 | -21.4953271028 | 5.35 | 7.5 | 4.14 | 924347 | 5.61778889 | CS |
| 52 | 0.98 | 30.4347826087 | 3.22 | 7.82 | 2.77 | 685138 | 5.27449725 | CS |
| 156 | 1.3 | 44.8275862069 | 2.9 | 10.48 | 1.04 | 528849 | 5.05265494 | CS |
| 260 | -6.03 | -58.9442815249 | 10.23 | 10.9584 | 1.04 | 349978 | 5.18422536 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.